PPIDT00014

Drug Information
NameGoserelin
SequencepEHWSYdS(tBu)LRPAzGlyNH₂
DrugBank_IDDB00014
Typesmall molecule
IndicationGoserelin is indicated for: - Use in combination with flutamide for the management of locally confined carcinoma of the prostate - Palliative treatment of advanced carcinoma of the prostate - The management of endometriosis - Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding - Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women

Dosage Forms
Form Route Strength
Implant —
Implant Parenteral; Subcutaneous
10.8 MG
Implant Parenteral; Subcutaneous
3.6 MG
Implant Subcutaneous
10.8 mg/1
Implant Subcutaneous
3.6 mg
Implant Subcutaneous
3.6 mg/1
Implant Subcutaneous
360000 mg
Implant Subcutaneous
1080000 mg
Implant —
10.8 mg
Implant —
3.6 mg
Injection Subcutaneous
3.6 mg
Implant Subcutaneous
10.8 mg
Injection Subcutaneous
10.8 mg
Solution —
3.6 mg
Solution —
10.8 mg
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P22888 LHCGR Lutropin-choriogonadotropic hormone receptor Homo sapiens agonist Link
target P01148 GNRH1 Progonadoliberin-1 Homo sapiens activator Link
target P30968 GNRHR Gonadotropin-releasing hormone receptor Homo sapiens agonist Link